| Literature DB >> 32107396 |
Mohamed M Said1,2, Cathy Watson3,4, Danilla Grando5.
Abstract
Vulvovaginal candidiasis causes sufferers much discomfort. Phytotherapy with garlic has been reported to be a possible alternative form of treatment; however, it is unknown why patients report varying success with this strategy. Fresh garlic extract has been shown to down-regulate the putative virulence gene, SIR2 in C. albicans. Our study aimed to see if previous observations were reproducible for the gene responsible for Candidalysin (ECE1). Two clinical strains from patients with reported variable efficacy of using garlic for the treatment of vulvovaginal candidiasis were compared through biofilm assays and antimicrobial susceptibility. Real-time PCR was used to assess changes in gene expression when exposed to garlic. Treatment with fresh garlic extract and pure allicin (an active compound produced in cut garlic) resulted in a decrease in SIR2 expression in all strains. In contrast, ECE1 expression was up-regulated in a reference strain and an isolate from a patient unresponsive to garlic therapy, while in an isolate from a patient responsive to garlic therapy, down-regulation of ECE1 occurred. Future studies that investigate the effectiveness of phytotherapies should take into account possible varying responses of individual strains and that gene expression may be amplified in the presence of serum.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32107396 PMCID: PMC7046767 DOI: 10.1038/s41598-020-60178-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
MIC50 and 90 of isolates as determined by broth microdilution assay.
| Strain and isolates | Fresh garlic extract | Fluconazole |
|---|---|---|
| MIC50/MIC90 (mg/ml) | MIC50/MIC90 (µg/ml) | |
| 0.05/0.4 | 2/4 | |
| 0.05/0.4 | 0.2/2 | |
| 0.05/0.4 | 0.2/2 |
Figure 1Distribution of C. albicans ATCC 14053 and clinical isolates 0861 and 1358 biofilm without garlic treatment in the presence and absence of 3% FBS. Bars indicate standard error of the mean (SEM).
Figure 2Distribution of C. albicans ATCC 14053 (A) and clinical isolates 0861 (B) and 1358 (C) biofilm at different concentrations of FGE in the presence and absence of 3% FBS. Bars indicate SEM.
Figure 3Relative quantitation of SIR2 expression normalized to the β-actin in C. albicans ATCC 14053 and clinical isolates 0861 and 1358 planktonic cells after 24 h of treatment with different concentrations of FGE and pure allicin by RT-PCR. Untreated samples of the three isolates were used as a reference to show the differences among strains. The * denotes significant reduction of gene expression to untreated control at levels ranges between P < 0.05 (*) and P < 0.0001 (****). Data shows the ratio of gene expression with bars indicating SEM.
Figure 4Relative quantitation of ECE1 expressions normalized to β-actin in C. albicans ATCC 14053 (A) and clinical isolate 0861 (B) and 1358 (C) in planktonic cells after 24 h of treatment with different concentrations of FGE and pure allicin showing a significant reduction of gene expression in clinical isolate 0861 while up-regulation is shown in ATCC strain and clinical isolate 1358 at all concentrations used compared to untreated control. The * denotes significant reduction of gene expression to untreated control at levels ranges between P < 0.05 (*) and P < 0.0001 (****). Data shows the ratio of gene expression with bars indicating SEM.
Figure 5Relative quantitation of ECE1 expression normalized to the β-actin gene in C. albicans ATCC 14053 and clinical isolates 0861 and 1358 biofilms after 24 h of treatment with and without 3% FBS. Untreated ATCC 14053 strain was used as a reference strain to show the differences among strains. (*) means a significant down-regulation (P < 0.05), (**) means a significant up-regulation of ECE1 expression (P < 0.01). All other difference observed were significant at P < 0.001. Bars indicate SEM.
Primer sequences used in real-time PCR transcriptional assay.
| Primer Full name | Orientation | Sequence (5′-3′) | Product length (bp) | Region | Reference |
|---|---|---|---|---|---|
| Forward | GTTGCTAATGCCGTCGTC | 98 | 397–494 | This study | |
| Reverse | TCTGGAACGCCATCTCTC | This study | |||
| Forward | TGGACCTGCAACTGGAAC | 205 | 532–537 | This study | |
| Reverse | CCTGCACCAGTAACTACC | This study | |||
| Forward | TCCAACTGGGACGATATG | 219 | 183–402 | This study | |
| Reverse | GGTGGTTCTACCAGAAGAG | This study |